Personalized treatment for HER2+ or triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial is testing whether checking DNA from your blood (circulating tumor DNA) can help doctors choose the best neoadjuvant (pre-surgery) treatment for HER2-positive or triple-negative breast cancer. It aims to personalize therapy based on how your tumor responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage II or III breast cancer that is either HER2-positive or triple-negative.
- You have not had any chemotherapy, hormone therapy, surgery, or radiation for this breast cancer yet.
- You are healthy enough to have surgery (ECOG score 0-2).
- You have a tumor that can be measured (at least 1 cm on ultrasound).
- You do not have inflammatory breast cancer, metastatic disease, or another cancer in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This study tests whether using a personalized approach to treatment after chemotherapy can improve outcomes for people with HER2-positive or triple-negative breast cancer. It aims to tailor further therapy based on how well the tumor responds initially.
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
This study is testing a research tool that may help doctors choose the best treatment for people with advanced triple-negative breast cancer. You will have a biopsy and blood draw to help see how the tool works.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.